1.腫瘤藥理學(xué)研究(Tumor Pharmacodynamics Study)
運(yùn)用分子生物學(xué)技術(shù)，腫瘤細(xì)胞株培養(yǎng)和體內(nèi)裸小鼠移植瘤模型等一系列腫瘤藥效評(píng)價(jià)體系，從分子、細(xì)胞和整體動(dòng)物三個(gè)水平全面系統(tǒng)深入地評(píng)價(jià)覆蓋細(xì)胞毒類(lèi)藥物、新生血管生成抑制劑、耐藥逆轉(zhuǎn)劑、分化誘導(dǎo)劑、受體或非受體型激酶抑制劑等分子靶向藥物的臨床前藥效及抗腫瘤作用機(jī)制研究。
Study on molecular, cellular and whole animal, use tumor efficacy evaluation system, such as molecular biology technology, tumor cell lines culturing and nude mice transplantation model and so on, to conduct preclinical drug efficacy and anti-tumor mechanism research on molecular targeted drugs which including: cytotoxic drugs, angiogenesis inhibitors, reversal agents, differentiation inducer, receptor or non-receptor tyrosine kinase inhibitors, etc.
2.心血管系統(tǒng)研究(Cardiovascular Pharmacodynamics Study)
主要針對(duì)治療心肌缺血、抗心律失常、抗高血壓、抑制血小板聚集和溶血栓藥物以及抗動(dòng)脈粥樣硬化和降血脂藥物的篩選及臨床前藥效學(xué)評(píng)價(jià)和機(jī)制研究。
Pre-clinical dug efficacy screening of drugs which have the following effects: myocardial ischemia treatment, anti-arrhythmia, anti-high blood pressure, inhibits platelet aggregation and thrombolytic effect, anti-atherosclerotic and blood lipid-lowering.
3.中樞神經(jīng)系統(tǒng)研究( Central Nervous PharmacodynamicsStudy)
針對(duì)目前臨床嚴(yán)重威脅人類(lèi)健康的重大疾病中風(fēng)建立了缺血性腦中風(fēng)（4動(dòng)脈閉塞全腦缺血模型、電凝/線栓/光化學(xué)法所致大腦中動(dòng)脈閉塞引起的局部性腦缺血模型）和缺氧-復(fù)氧、、炎癥因子等誘導(dǎo)大腦皮層原代神經(jīng)元細(xì)胞、海馬神經(jīng)元細(xì)胞、腦微血管內(nèi)皮細(xì)胞損傷模型，建立一系列涵蓋了從酶、受體、組織、整體動(dòng)物模型到模式化動(dòng)物等多個(gè)研究水平，全面系統(tǒng)地對(duì)抗缺血性腦損傷藥物進(jìn)行臨床前藥效學(xué)評(píng)價(jià)及作用機(jī)制研究。
Targeted on ischemic stroke, glutamic acid, anoxia-reoxygenation inflammation factor induced cell damage model, a series of enzymes, receptors, tissues, and whole animal models have been built, and then comprehensively and systematically conduct research on preclinical drug pharmacodynamics evaluation and efficacy mechanism.
4.內(nèi)分泌系統(tǒng)研究(Endocrine System Pharmacodynamics Study)
主要通過(guò)藥物和/或飲食誘導(dǎo)的Ⅰ型及Ⅱ型糖尿病模型及嚙齒類(lèi)動(dòng)物轉(zhuǎn)基因模型，運(yùn)用糖耐量和體外糖苷酶活性檢測(cè)方法、血糖鉗及分子生物學(xué)等技術(shù)全面開(kāi)展抗糖尿病及其他代謝疾病創(chuàng)新藥物的臨床前藥效和機(jī)制研究。
Study of drug & food induced Type Ⅰａnd Type Ⅱdiabetes model as well as rodents genetically modified model, use glucose tolerance, in vitro glycosidase activity detection method, blood glucose clamp and molecular biology technology to carry out comprehensive preclinical drug efficacy and mechanism research on drugs for diabetes and other metabolic diseases.
5.消化系統(tǒng)藥物藥效評(píng)價(jià)(Digestive System PharmacodynamicsStudy)
建立化學(xué)損傷、應(yīng)激損傷和免疫損傷引起的胃、腸潰瘍模型；體內(nèi)、外觀察胃、腸運(yùn)動(dòng)和動(dòng)作電位實(shí)驗(yàn)方法。
Establish gastric ulcer and enterelcosis model induced by chemical damage, stress damage and immune injury.
6.其他系統(tǒng)藥效評(píng)價(jià)(Pharmacodynamics Study on other system)
呼吸系統(tǒng)藥物藥效評(píng)價(jià)(Respiratory system pharmacodynamics study)
良性前列腺增生藥物藥效評(píng)價(jià)(Benign prostatic hypertrophy pharmacodynamics study)
皮膚疾病藥效學(xué)評(píng)價(jià)模型(Skin disease pharmacodynamics study)
會(huì)員1.png)
